Results 11 to 20 of about 88,199 (267)

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study

BMC Infectious Diseases, 2021
Background Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective ...
Andrew Ip, Jaeil Ahn, Yizhao Zhou, Andre H. Goy, Eric Hansen, Andrew L. Pecora, Brittany A. Sinclaire, Urszula Bednarz, Michael Marafelias, Ihor S. Sawczuk, Joseph P. Underwood, David M. Walker, Rajiv Prasad, Robert L. Sweeney, Marie G. Ponce, Samuel La Capra, Frank J. Cunningham, Arthur G. Calise, Bradley L. Pulver, Dominic Ruocco, Greggory E. Mojares, Michael P. Eagan, Kristy L. Ziontz, Paul Mastrokyriakos, Stuart L. Goldberg   +24 more
doaj   +1 more source

Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]

, 2020
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core   +1 more source

Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019

Annals of Medicine, 2021
Hydroxychloroquine, initially used as an antimalarial, is used as an immunomodulatory and anti-inflammatory agent for the management of autoimmune and rheumatic diseases such as systemic lupus erythematosus.
Pankaj Bansal, Amandeep Goyal, Austin Cusick, Shubham Lahan, Harpal S. Dhaliwal, Poonam Bhyan, Pradnya Brijmohan Bhattad, Fawad Aslam, Sagar Ranka, Tarun Dalia, Lovely Chhabra, Devang Sanghavi, Bhavin Sonani, John M. Davis   +13 more
doaj   +1 more source

COVID-19 and chronological aging : senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? [PDF]

, 2020
COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family.
Auwerx, Blagosklonny, Blagosklonny, Blagosklonny, Colasurdo, Colson, Diaz-Quijano, Du, Erusalimsky, Gerontol, Gorospe, Hoffmann, Häkkinen, Jang, Li, Lisanti, Lisanti, Lu, Masternak, Munster, Musso, Nowakowski, Porter, Subbarao, Subbarao, Tanga, Tremblay, Wilce, Yaron, Yusof, Zhang   +30 more
core   +2 more sources

The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers

Brazilian Journal of Infectious Diseases, 2022
Objectives: Comparative data on hydroxychloroquine and favipiravir, commonly used agents in the treatment of Coronavirus Disease-2019 (COVID-19), are still limited.
Derya Bayırlı Turan, Mehtap Menteş, Yıldıran Özel, Kıvanç Şerefhanoğlu, Burcu Aydoğan, Neşe İbil, Füsun Güneşdoğdu, Hijran Mammadova Orucova, Cüneyt Saltürk, Hakan Çelik   +9 more
doaj   +1 more source

Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? [PDF]

, 2011
No abstract ...
Amaravadi, Arunima Mukhopadhyay, Bellodi, Belloni, Boya, Druker, Furst, Gordon, Gozuacik, Gudmundur V Helgason, Jiang, Kalia, Kim, Maria Karvela, Munster, Naka, Ozvegy-Laczka, Savarino, Sharma, Tessa L Holyoake, Zaidi   +20 more
core   +1 more source

A call to caution when hydroxychloroquine is given to elderly patients with COVID-19

International Journal of Infectious Diseases, 2021
Introduction: Use of hydroxychloroquine in patients with coronavirus disease 2019 (COVID-19) was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk of hydroxychloroquine interactions with co-morbidities and co ...
Julian J. Gabor, Andrea Kreidenweiss, Stefan Weber, Moaaz Salama, Mihaly Sulyok, Zita Sulyok, Erik Koehne, Meral Esen, Benno Kreuels, Parichehr Shamsrizi, Erwin Biecker, Benjamin Mordmüller, Christoph P. Berg, Stefano Fusco, Carsten Köhler, Stefan Kubicka, Jens Leitlein, Marylyn Addo, Michael Ramharter, Matthias Schwab, Alfred Lennart Bissinger, Thirumalaisamy P. Velavan, Sanjeev Krishna, Peter G. Kremsner   +23 more
doaj   +1 more source

The multifocal pattern electroretinogram in chloroquine retinopathy [PDF]

, 2004
Purpose: Optimal screening for ocular toxicity caused by chloroquine and hydroxychloroquine is still controversial. With the multifocal pattern electroretinogram (mfPERG), a new electrophysiological technique has recently become available to detect early
Arden, G. B., Berninger, T., Neubauer, A. S., Rudolph, G., Stiefelmeyer, S.   +4 more
core   +1 more source

Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis

Journal of Nepal Health Research Council, 2021
Background: The global spread of COVID-19 and the lack of definite treatment have caused an alarming crisis in the world. We aimed to evaluate the outcome and potential harmful cardiac effects of hydroxychloroquine and azithromycin compared to ...
Pravash Budhathoki, Dhan Bahadur Shrestha, Sitaram Khadka, Era Rawal   +3 more
doaj   +1 more source